Sutro Biopharma (NASDAQ:STRO) is a clinical‐stage biotechnology company focused on developing innovative cancer therapies through its proprietary cell‐free protein synthesis platform, XpressCF®. This platform enables rapid production and optimization of novel biologics, including antibody‐drug conjugates (ADCs), bispecific antibodies and other protein modalities, with the goal of improving potency and manufacturability. By decoupling protein synthesis from living cells, XpressCF® offers researchers access to full control over protein composition, facilitating the design of homogeneous and high‐value therapies.
The company’s pipeline features several lead candidates in oncology indications. STRO‐001, an ADC targeting CD74, is being evaluated in patients with multiple myeloma and B‐cell malignancies. STRO‐002, another ADC directed against the folate receptor alpha, is under investigation in ovarian and endometrial cancers. Beyond these, Sutro is advancing a range of immuno‐oncology programs, including novel bispecific constructs that engage immune effector cells. Many of these programs are being developed both in‐house and in collaboration with global pharmaceutical partners.
Founded in 2003 and headquartered in South San Francisco, Sutro Biopharma serves a worldwide research and development community. The company has built a state‐of‐the‐art facility that integrates its XpressCF® lab capabilities with analytical and bioassay teams, allowing for end‐to‐end biologic design, screening and characterization. Sutro’s collaborative framework extends from academic institutions to major biopharmaceutical firms, reflecting its commitment to translating scientific innovation into potential therapies.
Leadership at Sutro includes CEO William Newell, who brings extensive experience in biotech commercialization and corporate strategy, and CSO Dr. Dennis Dougherty, a pioneer in chemical biology and protein engineering. Under their guidance, Sutro continues to refine its platform technology and expand its oncology pipeline, with the aim of bringing more precise and effective treatments to patients battling cancer.
